Paeonol ameliorates diabetic erectile dysfunction by inhibiting HMGB1/RAGE/NF‐kB pathway

Taotao Sun,Wenchao Xu,Jiaxin Wang,Jingyu Song,Tao Wang,Shaogang Wang,Kang Liu,Jihong Liu
DOI: https://doi.org/10.1111/andr.13203
2022-06-10
Andrology
Abstract:Background The management of diabetes mellitus‐induced erectile dysfunction (DMED) is progressively becoming tricky due to the surge in the number of patients and the poor efficiency of phosphodiesterase type 5 inhibitors in DMED. Paeonol (Pae), as a traditional Chinese medicine, has been more and more widely used in the treatment of diabetic complications. However, whether Pae could be a potential therapeutic drug of DMED needs to be further evaluated. Objectives To investigate the pharmacological effect and possible mechanism of Pae in the treatment of DMED. Methods Intraperitoneal streptozotocin injection and an apomorphine test were used to construct the model of DMED. Seventeen DMED rats were divided into 2 groups: DMED group (n = 8) and DMED+Pae group (Pae; 100 mg/kg/d; oral administration; n = 9). In addition, there were still 10 normal age‐matched male rats as control group. Four weeks later, the cavernous nerve electric stimulation was carried out to measure the erectile response. Moreover, the corpus cavernosum smooth muscle cells (CCSMCs) were primarily isolated and exposed to high glucose (HG) stimulation, Pae treatment and glycyrrhizin (GL; the selective inhibitor of HMGB1). After an incubation for 1 week, the CCSMCs were harvested for detection. Results The impairment of erectile dysfunction was observed in DMED rats compared with control samples, accompanied by the upregulation of HMGB1/RAGE/NF‐κB Pathway. The lower NO and cGMP level and the higher level of inflammation, fibrosis and apoptosis were also observed in DMED rats. It showed contrast that Pae treatment could improve the erectile function, as well as histologic alteration and related molecular changes. In addition, Pae could down‐regulate the HMGB1/RAGE/NF‐κB pathway to regulate the apoptosis and inflammation levels of CCSMCs in high‐glucose conditions, which is similar to the results of GL treatment. Conclusion Pae alleviated erectile dysfunction in DMED rats, likely by inhibiting HMGB1/RAGE/NF‐κB Pathway, inflammatory, apoptosis and fibrotic activity, and moderating endothelial dysfunction. Our study provide evidence for a potential new therapy for DMED. This article is protected by copyright. All rights reserved
andrology
What problem does this paper attempt to address?